Targeting PDE4 has been verified as an effective therapeutic strategy for chronic inflammatory conditions, including asthma, chronic obstructive pulmonary disease (COPD), psoriasis, atopic dermatitis, inflammatory bowel diseases (IBD), rheumatic arthritis (RA), and lupus [3,4]. This evidence concerns the gene PDE4A and inflammatory bowel disease.